JP2015107945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015107945A5 JP2015107945A5 JP2013252443A JP2013252443A JP2015107945A5 JP 2015107945 A5 JP2015107945 A5 JP 2015107945A5 JP 2013252443 A JP2013252443 A JP 2013252443A JP 2013252443 A JP2013252443 A JP 2013252443A JP 2015107945 A5 JP2015107945 A5 JP 2015107945A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition according
- hydrogen atom
- active ingredient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 210000002569 neuron Anatomy 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 230000004766 neurogenesis Effects 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000003367 polycyclic group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims 2
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- MOVHBYQABFWGEO-LCYFTJDESA-N CCN(C(C1C=COC1(C)C=C1)=C1S1)/C1=C/C(C)=O Chemical compound CCN(C(C1C=COC1(C)C=C1)=C1S1)/C1=C/C(C)=O MOVHBYQABFWGEO-LCYFTJDESA-N 0.000 description 1
- IZNKZNXIXHLRGY-JYRVWZFOSA-N CCN1c(c2c(cc3)OCC2)c3S/C1=C\C(C)=O Chemical compound CCN1c(c2c(cc3)OCC2)c3S/C1=C\C(C)=O IZNKZNXIXHLRGY-JYRVWZFOSA-N 0.000 description 1
- WJCUXFRHZYIEOR-YVLHZVERSA-N CCN1c(c2c(cc3)[o]c4c2ccc(C)c4)c3S/C1=C\C(C)=O Chemical compound CCN1c(c2c(cc3)[o]c4c2ccc(C)c4)c3S/C1=C\C(C)=O WJCUXFRHZYIEOR-YVLHZVERSA-N 0.000 description 1
- QIAFGVQZUDBBOX-YBEGLDIGSA-N CCN1c(c2c(cc3)[o]c4ccccc24)c3S/C1=C\C(C)=O Chemical compound CCN1c(c2c(cc3)[o]c4ccccc24)c3S/C1=C\C(C)=O QIAFGVQZUDBBOX-YBEGLDIGSA-N 0.000 description 1
- NHDNXYLLAQDNEW-PXNMLYILSA-N CCN1c2c(c(cc(cc3)Cl)c3[o]3)c3ccc2S/C1=C\C(C)=O Chemical compound CCN1c2c(c(cc(cc3)Cl)c3[o]3)c3ccc2S/C1=C\C(C)=O NHDNXYLLAQDNEW-PXNMLYILSA-N 0.000 description 1
- RUQRAQTVHSATEP-PXNMLYILSA-N CCN1c2c(c(ccc(Cl)c3)c3[o]3)c3ccc2S/C1=C\C(C)=O Chemical compound CCN1c2c(c(ccc(Cl)c3)c3[o]3)c3ccc2S/C1=C\C(C)=O RUQRAQTVHSATEP-PXNMLYILSA-N 0.000 description 1
- KAOGHERYRZIKQY-YVLHZVERSA-N CCN1c2c(c3cc(C)ccc3[o]3)c3ccc2S/C1=C\C(C)=O Chemical compound CCN1c2c(c3cc(C)ccc3[o]3)c3ccc2S/C1=C\C(C)=O KAOGHERYRZIKQY-YVLHZVERSA-N 0.000 description 1
- 0 Cc(nccc1c2ccc3OC)c1[n]c2c3C#C[Si](C)(C)* Chemical compound Cc(nccc1c2ccc3OC)c1[n]c2c3C#C[Si](C)(C)* 0.000 description 1
- NRBGMOGXBQRJJI-UHFFFAOYSA-N Cc1c2[nH]c(c(-c3cc(C(F)(F)F)ccc3)c(cc3)OC)c3c2ccn1 Chemical compound Cc1c2[nH]c(c(-c3cc(C(F)(F)F)ccc3)c(cc3)OC)c3c2ccn1 NRBGMOGXBQRJJI-UHFFFAOYSA-N 0.000 description 1
- XRKAGOQTYZDWCD-UHFFFAOYSA-N Cc1c2[nH]c(c(-c3ccc(C(F)(F)F)cc3)c(cc3)OC)c3c2ccn1 Chemical compound Cc1c2[nH]c(c(-c3ccc(C(F)(F)F)cc3)c(cc3)OC)c3c2ccn1 XRKAGOQTYZDWCD-UHFFFAOYSA-N 0.000 description 1
- FZIYPGBZXZEVAD-UHFFFAOYSA-N Cc1c2[nH]c(c(C#CC3(CC(C4)C5)CC5CC4C3)c(cc3)OC)c3c2ccn1 Chemical compound Cc1c2[nH]c(c(C#CC3(CC(C4)C5)CC5CC4C3)c(cc3)OC)c3c2ccn1 FZIYPGBZXZEVAD-UHFFFAOYSA-N 0.000 description 1
- HNEPVENUEAVPDF-UHFFFAOYSA-N Cc1c2[nH]c(c(C#CC3(CCCCC3)O)c(cc3)OC)c3c2ccn1 Chemical compound Cc1c2[nH]c(c(C#CC3(CCCCC3)O)c(cc3)OC)c3c2ccn1 HNEPVENUEAVPDF-UHFFFAOYSA-N 0.000 description 1
- NNBDGHSCJXGLIV-UHFFFAOYSA-N Cc1c2[nH]c(c(C#Cc3ccccc3)c(cc3)OC)c3c2ccn1 Chemical compound Cc1c2[nH]c(c(C#Cc3ccccc3)c(cc3)OC)c3c2ccn1 NNBDGHSCJXGLIV-UHFFFAOYSA-N 0.000 description 1
- XSJFNYCFKORWJZ-UHFFFAOYSA-N Cc1cc(C)cc(-c(c2c(cc3)c4ccnc(C)c4[nH]2)c3OC)c1 Chemical compound Cc1cc(C)cc(-c(c2c(cc3)c4ccnc(C)c4[nH]2)c3OC)c1 XSJFNYCFKORWJZ-UHFFFAOYSA-N 0.000 description 1
- IIUIFEXOMDUOPE-UHFFFAOYSA-N Cc1cccc(-c(c2c(cc3)c4ccnc(C)c4[nH]2)c3OC)c1 Chemical compound Cc1cccc(-c(c2c(cc3)c4ccnc(C)c4[nH]2)c3OC)c1 IIUIFEXOMDUOPE-UHFFFAOYSA-N 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013252443A JP2015107945A (ja) | 2013-12-05 | 2013-12-05 | 神経新生に関する化合物及び医薬組成物 |
| PCT/JP2014/082035 WO2015083750A1 (ja) | 2013-12-05 | 2014-12-03 | 神経新生に関する化合物及び医薬組成物 |
| US15/101,862 US20160303089A1 (en) | 2013-12-05 | 2014-12-03 | Compound pertaining to neuropoiesis and drug composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013252443A JP2015107945A (ja) | 2013-12-05 | 2013-12-05 | 神経新生に関する化合物及び医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015107945A JP2015107945A (ja) | 2015-06-11 |
| JP2015107945A5 true JP2015107945A5 (enExample) | 2017-01-19 |
Family
ID=53273511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013252443A Pending JP2015107945A (ja) | 2013-12-05 | 2013-12-05 | 神経新生に関する化合物及び医薬組成物 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20160303089A1 (enExample) |
| JP (1) | JP2015107945A (enExample) |
| WO (1) | WO2015083750A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2917628A1 (en) * | 2013-09-12 | 2015-03-19 | F. Hoffmann-La Roche Ag | Indol-carboxamide derivatives |
| JP7054524B2 (ja) * | 2016-08-31 | 2022-04-14 | 国立大学法人京都大学 | 神経新生を活性化するための組成物 |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| CN114432318A (zh) * | 2017-02-20 | 2022-05-06 | 国立大学法人京都大学 | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 |
| JPWO2021153665A1 (enExample) * | 2020-01-30 | 2021-08-05 | ||
| EP4129340B1 (en) * | 2020-04-01 | 2025-12-03 | Kyoto University | Suppression of neuroinflammation and composition and method therefor |
| WO2022059779A1 (ja) * | 2020-09-18 | 2022-03-24 | 大日本住友製薬株式会社 | アミン誘導体 |
| EP4303304A4 (en) * | 2021-03-03 | 2025-03-05 | Riken | POLYNUCLEOTIDE FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE, VECTOR, CELL, PHARMACEUTICAL COMPOSITION AND SCREENING METHOD |
| JPWO2022255411A1 (enExample) | 2021-06-01 | 2022-12-08 | ||
| JPWO2023008472A1 (enExample) * | 2021-07-28 | 2023-02-02 | ||
| WO2023008470A1 (ja) * | 2021-07-28 | 2023-02-02 | 住友ファーマ株式会社 | 縮環アミン誘導体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003273351A1 (en) * | 2002-09-24 | 2004-04-19 | Isis Pharmaceutical, Inc. | Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors |
| EP2164494A4 (en) * | 2007-06-01 | 2010-06-02 | Glaxosmithkline Llc | Methods of Treatment |
| KR20100010894A (ko) * | 2008-07-23 | 2010-02-02 | 가부시키가이샤 키노파마 | Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물 |
| CA2774558A1 (en) * | 2009-09-22 | 2011-03-31 | Neuronascent, Inc. | Methods and pharmaceutical compositions for treating down syndrome |
| WO2011068990A1 (en) * | 2009-12-04 | 2011-06-09 | Medipropharma, Inc. | Compositions and methods for inhibiting dyrk1a to treat central nervous system diseases and disorders |
| WO2011133795A2 (en) * | 2010-04-22 | 2011-10-27 | The Brigham And Women's Hospital, Inc. | Beta-carbolines as inhibitors of haspin and dyrk kinases |
| CA2848896C (en) * | 2011-08-19 | 2019-10-29 | Diaxonhit | Dyrk1 inhibitors and uses thereof |
| JPWO2013183718A1 (ja) * | 2012-06-06 | 2016-02-01 | 国立大学法人京都大学 | スクリーニング方法、タンパク質の不安定性及び／又は安定性を誘導する物質、及び、タンパク質の活性評価 |
| WO2014021337A1 (ja) * | 2012-07-30 | 2014-02-06 | 国立大学法人京都大学 | 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 |
-
2013
- 2013-12-05 JP JP2013252443A patent/JP2015107945A/ja active Pending
-
2014
- 2014-12-03 WO PCT/JP2014/082035 patent/WO2015083750A1/ja not_active Ceased
- 2014-12-03 US US15/101,862 patent/US20160303089A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015107945A5 (enExample) | ||
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| PE20190662A1 (es) | Composiciones farmaceuticas que contienen derivados de piridona policiclicos sustituidos y profarmaco de los mismos | |
| JP2016510000A5 (ja) | 治療用化合物 | |
| RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
| JP2006508091A5 (enExample) | ||
| JP2017527561A5 (enExample) | ||
| JP2017523152A5 (enExample) | ||
| JP2014507421A5 (enExample) | ||
| WO2017176620A3 (en) | SOLUBLE C5aR ANTAGONISTS | |
| MX2013007295A (es) | Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2. | |
| JP2016537382A5 (enExample) | ||
| EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
| JP2020509018A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2014511892A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| MA32570B1 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| HK1210771A1 (zh) | 氮杂吲哚衍生物 | |
| JP2015516427A5 (enExample) | ||
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| JP2018514522A5 (enExample) | ||
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof |